THE TREND IS YOUR FRIEND LIKE down The Illuminati and One World Government From Genesis to the Tower of Babel, to the Egyptian Pharaohs, to Goat God's, to the World Bank, and the FreeMasons, Secret Societies, Rosicrucians, Rothschild bloodline, sexual perversions, Marxism, Communism, Illuminati, Evil 666 -
Finally, Apexigen has pulled an about-face since the start of the new year. The company hit fresh, 52-week lows on the first day of trading for 2023 but so far has bounced back more than 100%. If analysts are to be believed, they expect much more, which we’ll discuss later in this section.
Apexigen develops antibody-based therapeutics for cancer treatment and recently posted new Phase 2 data. This data evaluated its sotigalimab in treating tumors in patients with esophageal/gastro-esophageal junction (E/GEJ) cancer and a separate study in rectal cancer tumors. The data was recently presented at the ASCO Gastrointestinal Cancers Symposium earlier this month.
Recent news regarding a $2.8 million financing deal doesn’t seem to have impacted the market. The funding round is expected to close by the end of this month, with proceeds going toward the ongoing Phase 2 study of sotigalimab.
What is the APGN stock forecast? Roth Capital recently reinstated its coverage of the company. The firm gave a Buy rating and price target of $15. APGN stock closed at $1.99 on Tuesday, which puts Roth Capitals forecast 654% higher.
APGN: OLD "news" from 1-4-23 --- re-hashed to look EPIC for the Monday MARKETS!! PURE suckers' bait for today, Bro!! Did YOU jump-on-it right out of the starting gate????? I, too, almost grabbed some early today, but knew better. GOOD LUCK!!!
APEXIGEN (APGN) STOCK JUMPED 126.8% ON POSITIVE STOCK RATING
The Apexigen Inc (NASDQ: APGN) stock jumped 126.8% after EF Hutton Acquisition Co. initiated coverage of the stock with an $8.00 price target and a buy rating. The rating was issued on Wednesday, January 4, 2022, reigniting investor interest in the company.
The last significant announcement from the company was the release of its Q3 earnings results on November 15, 2022, where its earnings per share rose to $0.41, representing a slight improvement to last year’s $0.40 figure.